Dysmenorrhea Pipeline Assessment, Clinical Trial, Key Companies, And Emerging Drugs by DelveInsight

Dysmenorrhea Pipeline Assessment, Clinical Trial, Key Companies, And Emerging Drugs by DelveInsight

Dysmenorrhea Pipeline

Dysmenorrhea Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Dysmenorrhea Market. 

The assessment part of the report embraces in-depth Dysmenorrhea commercial assessment and clinical assessment of the Dysmenorrhea pipeline products from the pre-clinical developmental phase to the marketed phase. 

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dysmenorrhea collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


Get FREE sample copy at:


The dynamics of the Dysmenorrhea market is anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&D activities.

Dysmenorrhea Companies:

  • Takeda
  • Mochida
  • AbbVie
  • ObsEva SA
  • Fuji Pharma’s
  • Nobelpharma
  • Nippon Shinyaku
  • ASKA Pharmaceutical
  • Myovant Sciences GmbH
  • Pure Green Pharmaceuticals
  • Neurosciences Biosciences
  • And many others.


Dysmenorrhea Therapies covered in the report include:

  • Pure Femme Tablets
  • FSN-013
  • Yselty
  • Relugolix
  • And many others.


Dysmenorrhea Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Dysmenorrhea with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Dysmenorrhea treatment.
  • Dysmenorrhea key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dysmenorrhea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dysmenorrhea market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  


Get FREE sample copy at:


 Scope of the report

  • The Dysmenorrhea Pipeline Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Dysmenorrhea across the complete product development cycle, including all clinical and non-clinical stages.
  • It comprises detailed profiles of Dysmenorrhea therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
  • Detailed research and development progress and clinical trial of Dysmenorrhea, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Dysmenorrhea.

 Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Dysmenorrhea.    
  • In the coming years, the Dysmenorrhea market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dysmenorrhea Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Dysmenorrhea treatment market. Several potential therapies for Dysmenorrhea are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Dysmenorrhea market size in the coming years.  
  • Our in-depth analysis of the Dysmenorrhea pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 


Get FREE sample copy at:


Table of Content

  1. Report Introduction
  2. Dysmenorrhea 
  3. Dysmenorrhea Current Treatment Patterns
  4. Dysmenorrhea – DelveInsight’s Analytical Perspective
  5. Therapeutic Assessment
  6. Dysmenorrhea Late Stage Products (Phase-III)
  7. Dysmenorrhea Mid Stage Products (Phase-II)
  8. Early Stage Products (Phase-I)
  9. Pre-clinical Products and Discovery Stage Products
  10. Inactive Products
  11. Dormant Products
  12. Dysmenorrhea Discontinued Products
  13. Dysmenorrhea Product Profiles
  14. Dysmenorrhea Key Companies
  15. Dysmenorrhea Key Products
  16. Dormant and Discontinued Products
  17. Dysmenorrhea Unmet Needs
  18. Dysmenorrhea Future Perspectives
  19. Dysmenorrhea Analyst Review  
  20. Appendix
  21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 


About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/dysmenorrhea-pipeline-insight?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr